[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tumor-induced-osteomalacia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tumor-induced-osteomalacia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100621090","al18f-nota-lm3-petct-in-patients-with-tio-100621090",false,"NCT07366099","Al18F-NOTA-LM3 PET\u002FCT in Patients With TIO","Application of Al18F-NOTA-LM3 PET\u002FCT in the Diagnosis and Evaluation of Tumor-Induced Osteomalacia","Inclusion Criteria:\n\n* Patients aged 18 to 80 years.\n* Suspected or confirmed TIO patients.\n\nExclusion Criteria:\n\n* Combined with other types of tumors.\n* Severe liver or renal dysfunction (ALT\u002FAST≥5 ULN, GFR\\\u003C30ml\u002Fmin).\n* Pregnant or breast-feeding women.\n* Inability to perform PET\u002FCT scans.","ALL","18 Years","80 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a pilot study to assess the value of whole-body Al18F-NOTA-LM3 PET\u002FCT in patients with tumor-induced osteomalacia.",[27],"Tumor-Induced Osteomalacia","RECRUITING","2026-01-18",{"date":31,"type":32},"2026-01-26","ACTUAL",{"date":34,"type":32},"2023-03-30",{"date":36,"type":21},"2026-05-30",{"name":38,"class":39},"Peking Union Medical College Hospital","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":4,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":47,"phases":4,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":60,"locationsCount":4},"100345245","expanded-access-to-burosumab-100345245","NCT03775187","Expanded Access to Burosumab","Inclusion Criteria:\n\n\\-\n\nExclusion Criteria:\n\n\\-","EXPANDED_ACCESS","Individual patient expanded access requests may be considered for patients who have no other treatment options",[50,27],"X-linked Hypophosphatemia",[52,53,54,55],"Expanded Access","Compassionate Use","XLH","TIO","AVAILABLE","2025-02-28",{"date":59,"type":32},"2025-03-05",{"name":61,"class":62},"Kyowa Kirin Co., Ltd.","INDUSTRY"]